Accelerate Your Fibrosis Research

Why is the world focusing on the PDE4B inhibitor (BI 1015550) as the next-generation IPF treatment following Ofev/Esbriet? We explain why "PDE4B"? its precise selectivity mechanism, the Phase 3 trial FIBRONEER-IPF results, and the path to approval.

With the weapons of Resmetirom and Semaglutide in hand, where is humanity heading next? We explore next-generation drugs like FGF21 analogs (Pegozafermin), game-changing NITs (Non-Invasive Tests), and concrete strategies for "Combination Therapy".

Semaglutide demonstrated remarkable results in the ESSENCE trial. This article explores its mechanism (direct vs. indirect), efficacy on non-invasive markers like ELF score, and the debate surrounding its application for "Lean MASH".